Go to content


China Briefings

Reports on China issued by Samsung Economic Research Institute

China Business Intelligence No. 205

China Business Intelligence No. 205

Samsung Economic Research Institute Beijing Office

Sept. 27, 2011

Download China Business Intelligence No. 205 PDF email Print

China has ramped up the production of agriculture and livestock products by successfully developing new GMO varieties and tightened safety monitoring of GMO products. In 2008-2010, China cultivated 36 insect-resistant cotton varieties and supplied them to 167 million mu (Chinese land unit: 666.7 ㎡ ) of land, posting 16 billion yuan in profit and a 93% market share. Meanwhile, the biopharmaceutical industry's 2010 total sales exceeded 100 billion yuan, over-achieving the goal set under the 11 th Five-Year Plan. In 2006-2010, the biopharmaceutical industry's sales shot up 272%. The biopharmaceutical industry's development, however, has been mainly driven by generic drugs and active pharmaceutical ingredients (API) because China's biopharmaceutical companies are weak in independent R&D capability. The central government has unleashed a series of support policies for the biopharmaceutical industry, one of the new industries intensively supported by the 12 th Five-Year Plan. The development of China 's biotechnology also offers opportunities to foreign-invested companies packed with advanced technology and financial power.

For full text (8 pages), click the PDF icon on top.
Go to list